Premium
Growth Hormone Receptor In Human Subcutaneous Adipose Tissue: Gluteal Versus Abdominal Depots
Author(s) -
Karastergiou Kalypso,
Bredella Miriam A,
Smith Steven R,
Miller Karen K,
Fried Susan K
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.630.3
Subject(s) - adipose tissue , medicine , endocrinology , growth hormone receptor , perilipin , abdominal fat , lipolysis , obesity , hormone , growth hormone
Central fat accumulation is associated with increased cardiometabolic risk and reduced growth hormone (GH) secretion. GH administration in obese premenopausal women reduced abdominal fatness and systemic inflammation, but had no effect on gluteal fat (Bredella MA et al, Eur J Endocrinol, 2012). To gain insight into the mechanisms underlying the depot‐specific effects of GH, we examined the expression of the GH receptor (GHR), as well as genes that GH may target in the lipolytic pathway, in samples of abdominal and gluteal subcutaneous adipose tissue from premenopausal women (n=16, BMI 27.3±4.0 kg/m2) and age‐matched men (n=28, BMI 26.8±6.1 kg/m2). GHR expression (by qPCR) was significantly lower in the gluteal compared to the abdominal depot (p=0.01). In both sites, GHR mRNA levels correlated significantly with ATGL (abdominal: r=0.62, p=0.0001, gluteal: r=0.61, p=0.0004) and perilipin expression (abdominal: r=0.63, p<0.0001, gluteal: r=0.69, p<0.0001). In the abdominal, but not in the gluteal depot, GHR also correlated with mRNA levels of HSL (r=0.68, p=0.0001), CIDEA (r=0.51, p=0.003) and CIDEC (r=0.47, p=0.006). These associations were statistically independent of BMI, age and sex. We conclude that depot differences in GHR expression may underlie the in vivo effect of GH administration to reduce specifically abdominal adipose tissue mass.